Physician profile
Benedict E Ewaleifoh
NPI 1649294265
$9,032.69
in general payments reported to CMS, 2019-2025
35 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $894 · 2021: $718 · 2022: $1,249 · 2023: $1,661 · 2024: $1,445 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,156 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,155.52 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,706.31 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $815.92 | 2019-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $781.36 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genzyme Corporation | $491.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $489.54 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Insmed, INC. | $301.59 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $282.77 | 2022-2025 | Dupixent |
| Abiomed | $221.42 | 2024-2025 | Impella |
| Mylan Specialty L.P. | $163.08 | 2019-2024 | Yupelri |
| Abbvie INC. | $155.05 | 2021-2025 | |
| Electromed, INC. | $148.72 | 2024-2025 | Smartvest |
| Janssen Pharmaceuticals, INC | $146.88 | 2020-2022 | |
| Verona Pharma, INC. | $146.71 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $142.16 | 2021-2025 | Glassia |
| Inari Medical, INC. | $119.82 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $117.22 | 2020-2025 | Vest Therapy Und |
| Genentech USA, INC. | $103.05 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $98.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.47 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $60.45 | 2020-2023 | Acthar |
| Ambu INC. | $54.01 | 2022-2025 | |
| Gilead Sciences, INC. | $53.81 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $46.15 | 2025 | Zerbaxa |
| Bayer Healthcare Pharmaceuticals INC. | $45.86 | 2021-2022 | |
| 3b Medical, INC. | $45.49 | 2024-2025 | Luna |
| Amgen INC. | $43.77 | 2023-2025 | Tezspire |
| Viatris Specialty LLC | $40.96 | 2025 | Yupelri |
| United Therapeutics Corporation | $39.68 | 2023-2025 | Tyvaso, Tyvaso |
| Boston Scientific Corporation | $16.57 | 2021 | |
| Grifols USA, LLC | $16.49 | 2025 | Prolastin-C Liquid |
| Covidien LP | $15.23 | 2019 | |
| Advanced Respiratory, INC | $14.57 | 2020 | |
| Pfizer INC. | $14.27 | 2020 | |
| Allergan, INC. | $12.55 | 2020 | |
| Circassia INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedict Ewaleifoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.